News
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant
Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...
GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...
12hon MSN
A renowned name in rare blood disorders research, Prof. Khaled Musallam has become the first Arab to receive the Clinical ...
Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...
First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results